Wilson Asset Management International PTY Ltd. Purchases 3,197 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Wilson Asset Management International PTY Ltd. raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.9% in the third quarter, HoldingsChannel.com reports. The firm owned 26,219 shares of the medical research company’s stock after buying an additional 3,197 shares during the period. Thermo Fisher Scientific comprises 3.9% of Wilson Asset Management International PTY Ltd.’s holdings, making the stock its 12th largest position. Wilson Asset Management International PTY Ltd.’s holdings in Thermo Fisher Scientific were worth $16,218,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. abrdn plc boosted its position in shares of Thermo Fisher Scientific by 1.6% during the third quarter. abrdn plc now owns 269,463 shares of the medical research company’s stock valued at $165,041,000 after buying an additional 4,122 shares during the last quarter. Pallas Capital Advisors LLC boosted its holdings in Thermo Fisher Scientific by 0.7% during the 3rd quarter. Pallas Capital Advisors LLC now owns 11,752 shares of the medical research company’s stock worth $7,269,000 after acquiring an additional 76 shares during the last quarter. Hunter Associates Investment Management LLC grew its stake in shares of Thermo Fisher Scientific by 2.4% in the 3rd quarter. Hunter Associates Investment Management LLC now owns 14,054 shares of the medical research company’s stock worth $8,691,000 after acquiring an additional 334 shares in the last quarter. Strategic Wealth Investment Group LLC lifted its position in shares of Thermo Fisher Scientific by 87.1% during the third quarter. Strategic Wealth Investment Group LLC now owns 21,675 shares of the medical research company’s stock valued at $13,286,000 after purchasing an additional 10,090 shares in the last quarter. Finally, Orrstown Financial Services Inc. boosted its holdings in Thermo Fisher Scientific by 251.0% during the third quarter. Orrstown Financial Services Inc. now owns 1,811 shares of the medical research company’s stock worth $1,120,000 after purchasing an additional 1,295 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Down 0.3 %

Shares of Thermo Fisher Scientific stock opened at $552.68 on Tuesday. The company’s 50-day moving average price is $604.03 and its 200-day moving average price is $583.92. The company has a market cap of $211.12 billion, a price-to-earnings ratio of 34.65, a PEG ratio of 3.66 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $420.21 and a 12-month high of $627.88. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same period in the previous year, the business earned $5.69 EPS. The business’s revenue for the quarter was up .2% on a year-over-year basis. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on TMO. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Raymond James boosted their price objective on Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Bank of America raised their target price on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a “buy” rating in a research report on Monday, September 16th. JPMorgan Chase & Co. increased their price target on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research report on Friday, September 20th. Finally, Bernstein Bank lifted their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 22nd. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $649.33.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $76,420,473.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.